GW Pharma
GW Pharma takes back control of UK Sativex sales from Bayer
March 2, 2020Sales and Marketing Bayer, GW Pharma, Sativex, UK
British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …
NHS to utilise first-ever cannabis-based therapies following NICE recommendation of two GW Pharma drugs
November 11, 2019Sales and Marketing Epidyolex, GW Pharma, NHS, Sativex, pharma
The NHS is authorised to use its first two cannabis-based medicines for routine use after NICE saw fit to recommend …
NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy
August 27, 2019Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma
UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …
GW Pharma’s cannabis-based Epidyolex edges closer to EU approval with positive CHMP opinion in epilepsy
July 26, 2019Medical Communications, Sales and Marketing EMA, Epidiolex, Europe, GW Pharma, cannabis, epilepsy
UK-based biotech GW Pharmaceuticals has announced that its cannabidiol oral solution Epidyolex has secured recommendation from the European Medicines Agency’s …
GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial
May 7, 2019Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc
GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …
Australian firm Althea enters UK medicinal cannabis market
February 13, 2019Research and Development Epidiolex, GW Pharma, Medical marijuana, NHS, UK, cannabis
Melbourne-based medicinal cannabis company Althea has become one of the first companies to enter the UK market after the British …
GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States
November 2, 2018Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis
GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …
Zynerba’s cannabis-based transdermal patch fails at Phase 1, shares slide 21%
July 6, 2018Medical Communications, Research and Development GW Pharma, Zynerba, cannabidinol, cannabinol, cannabis, pharma, trial failure
As public focus on the issue of medicinal cannabis continues to grow, Zynerba Pharmaceuticals has announced that its transdermal tetrahydrocannabinol …
GW Pharma’s Epidiolex becomes first cannabis-based medicine available in US
June 26, 2018Manufacturing and Production, Sales and Marketing FDA, GW Pharma, Lennox-Gastaut syndrome, UK, US, cannabidiol, cannabis
In what could prove to be a pivotal decision, UK biotech GW Pharmaceuticals has announced that its oral cannabidiol solution …
Top Ten most popular articles on Pharmafile.com this week
April 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical
It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
FDA advisory committee sets GW Pharma up for approval
April 20, 2018Medical Communications, Sales and Marketing Epidiolex, GW Pharma, biotech, drugs, pharma, pharmaceutical
After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …
All indications point to approval for cannabis-based therapy
April 17, 2018Research and Development, Sales and Marketing FDA, GW Pharma, biotech, drugs, pharma, pharmaceutical
GW Pharma are inching step by step towards a likely approval with the FDA, after it received a strong recommendation …
GW Pharma boasts new positive data, readying for approval
January 25, 2018Research and Development GW Pharma, biotech, drugs, pharma, pharmaceutical
The latest data from GW Pharma is about as conclusively positive as you can usually hope to get with a …
GW Pharma applies to both EU and US for lead product
January 2, 2018Manufacturing and Production, Sales and Marketing GW Pharma, biotech, drugs, pharma, pharmaceutical
GW Pharmaceuticals had a busy festive period, after it announced that it had submitted to both the EU and the …
Biotech’s stock goes down in flames after cannabidiol drug failure
August 8, 2017Manufacturing and Production, Research and Development GW Pharma, Zynerba, biotech, cannabidoil, drugs, pharma, pharmaceutical
Zynerba Pharmaceuticals had hoped that its anti-seizure therapy could replicate the kind of success leading competitors had achieved in showing …
Latest content
FibroFind appoints Lee Borthwick as CEO
